Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report
October 25 2022 - 8:30AM
Agenus (NASDAQ: AGEN) an immuno-oncology company with an extensive
pipeline of therapeutics designed to activate the immune response
to cancers and infections, today announced the Company will release
its second quarter 2022 financial results before the market opens
on Tuesday, November 8, 2022. Agenus executives will host a
conference call and webcast at 8:30 a.m. ET that morning to discuss
the results and to provide a corporate update.
Conference CallDial-in numbers: (646) 307-1963
(US-NY) or (800) 715-9871 (US & CA)Event ID: 6199615
WebcastA webcast and replay of the conference
call will be accessible from the Events & Presentations page of
the Company’s website at
https://investor.agenusbio.com/events-and-presentations and via
https://edge.media-server.com/mmc/p/xh3u6boi.
“The Road Taken” R&D EventAgenus will host
an in-person and virtual R&D event (“The Road Taken”) on
Saturday, November 12th, 2022, from 2:00 p.m. to 5:00 p.m. ET at
the Prudential Tower in Boston, MA. The event will feature insights
from leading cancer immunologists who will share their collective
and individual expertise on the current and future state of cancer
immunotherapy, including a deep dive into the botensilimab data
presented at SITC. Institutional investors, research analysts, and
key opinion leaders are invited to attend the Event in-person and
can RSVP by emailing investorrelations@agenusbio.com. To register
for the live webcast, please click here.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer and
infections. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its subsidiary MiNK
Therapeutics), and adjuvants (through its subsidiary SaponiQx). The
Company is equipped with a suite of antibody discovery platforms
and a state-of-the-art GMP manufacturing facility with the capacity
to support clinical programs. Agenus is headquartered in Lexington,
MA. For more information, please visit www.agenusbio.com and our
Twitter handle @agenus_bio. Information that may be important to
investors will be routinely posted on our website and Twitter.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements relating to our technologies, therapeutic candidates,
and capabilities, for instance, statements regarding therapeutic
benefit and efficacy, mechanism of action, potency, durability, and
safety and tolerability profile of our therapeutic candidates, both
alone and in combination with each other and/or other agents;
statements regarding future plans, including research, clinical,
regulatory, and commercialization plans; and any other statements
containing the words "may," "believes," "expects," "anticipates,"
"hopes," "intends," "plans," "will" and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Quarterly Report
on Form 10-Q or Annual Report on Form 10-K filed with the
Securities and Exchange Commission and available on our website:
www.agenusbio.com. Agenus cautions investors not to place
considerable reliance on the forward-looking statements contained
in this release. These statements speak only as of the date of this
press release, and Agenus undertakes no obligation to update or
revise the statements, other than to the extent required by law.
All forward-looking statements are expressly qualified in their
entirety by this cautionary statement.
ContactAgenus Inc.Nico
FrelickInvestor Relations781-674-4616nico.frelick@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024